Bioxytran Q3: $74K Cash, Going Concern, Defaulted Note and New Lawsuit
BIXT is trading near its 52-week low of $0.02 (10.0% above the low).
Summary
Bioxytran's Q3 10-Q shows $74,369 of cash, a $6.38M working-capital deficit and a going-concern warning, with its 2021 convertible note still in default and a new $1.35M lawsuit from a former officer.
Key Events · Earnings and Guidance · BIXT
-
Going Concern With $74K Cash
Cash stood at $74,369 on September 30, 2026, down from $509,914 at December 31, 2025, with negative working capital of $6,381,654 and an accumulated deficit of $25,011,000.
-
Nine-Month Loss Widens to $3.97M
The nine-month net loss reached $3,966,754 versus $1,600,922 a year earlier, driven largely by a $964,994 non-cash change in fair value of the embedded derivative and a $1,278,600 stock-based CEO performance grant.
-
Convertible Note Still in Default
The 2021 Note carries $805,000 principal plus $386,333 accrued interest, has been in default since March 1, 2025 at an 18% default rate, and its derivative liability stands at $1,368,347, above the note's own principal.
-
New $1.35M Lawsuit From Ex-Officer
Served October 6, 2026 in Nevada, the suit seeks $1,346,000 in wrongful-termination pay, challenges lock-up of 41,073,600 common-equivalent shares and the 30,000,000-share CEO grant, and seeks to halt nutraceutical sales; no accrual has been recorded.
Analysis · BIXT · Life Sciences
Bioxytran closed September 30, 2026 with just $74,369 of cash against $6.46M of current liabilities, leaving a $6.38M working-capital hole, and management again warns that these conditions raise substantial doubt about its ability to continue as a going concern. Only $322,423 was raised in the nine months through private placements, while the company says it needs roughly $3.7M to fund 15 months of operations, so survival hinges on selling more stock into a $0.022 share price. The $805,000 2021 convertible note has been in default since March 1, 2025 at an 18% default rate, and its embedded derivative now sits at $1,368,347, larger than the note itself, after a $964,994 non-cash mark-to-market charge that drove most of the $3.97M nine-month loss. On top of that, a new Nevada lawsuit from a fired officer seeks $1,346,000 in termination pay and challenges the 30,000,000-share (common-equivalent) grant to the CEO, while a material weakness in internal controls has been reaffirmed.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BIXT was trading at $0.02 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.5M. The 52-week trading range was $0.02 to $0.09. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.